Meihua, a commercial-stage, total solution provider for clinical microbiology diagnosis based in China, has recently completed its Series B funding, led by Eight Roads.  The proceeds will be used for product research and development, as well as accelerate the company’s market promotion to further expand its market share in the industry.

Founded in 2010, Meihua provides one-stop solutions for clinical microbiology laboratory. The company was formed by industry veterans who have strong commitments to the clinical microbiology industry and strive to make Meihua the clinical microbiology leading player in China. 

Dr. Lei Shi, Partner at Eight Roads, said: “Eight Roads is committed to long-term investment in China’s healthcare ecosystem and we have been closely monitoring the clinical unmet needs. Clinical microbiology testing is the gold standard for infectious disease diagnosis, guiding precision medicine in patients and beneficial to society in the prevention of drug resistance. Meihua is one of the market leaders in the industry and continues to expand its product portfolio and business over the years. We are very pleased to partner with Meihua to support the company’s long-term development and build the leading clinical microbiology platform not only in China but in the world.”